Continued Developments in Cancer Immunotherapy Brings Together Researchers and Industry Professionals

Mar 07, 2016, 08:36 ET from MarketsandMarkets Conferences

PUNE, India, March 7, 2016 /PRNewswire/ --

Cancer immunotherapy - a treatment that destroys developing tumors by identifying them and stimulating the human immune system - has seen massive developments in the last few years. It is said there will be explosive growth in the next year or so. Many pharma and bio-pharma companies are collaborating with research institutions to fruitfully utilize these developments and work towards developing personalized medicine. According to a recent article featured on GenomeWeb website, France's companion diagnostics company ImmunID, has entered into a deal with Memorial Sloan Kettering Cancer Center - MSKCC, to validate ImmunTracker assay, one of its products to test patient response.

http://www.mnmconferences.com/The-Cancer-Immunotherapy-Congress

     (Logo: http://photos.prnewswire.com/prnh/20160303/792302 )

In light of these recent advancements, MarketsandMarkets Conferences is organizing the Cancer Immunotherapy Congress, that will take place on the 19th and 20th of May 2016 in Boston - USA. The congress will gather scientists, academicians and professionals from pharmaceutical and bio-pharmaceutical companies, bio-technology firms and research institutes, working in drug discovery, drug screening, oncology R&D, cancer immuno-oncology and immunotherapy R&D. Dendreon Pharmaceuticals, TESARO, Jounce Therapeutics, Johnson & Johnson Innovation, Novartis Oncology Translational Research, Merck, Center For Cancer Research, Bellicum Pharmaceuticals, Mount Sinai School Of Medicine, Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, Boston Medical Centre and Agenus are some of the organizations participating in the congress.

An effective blend of case studies, presentations and panel discussions will focus on current developments in cellular immunotherapy, predictive biomarkers for response, combinational therapy and toxicity, new immunotherapy targets and pre-clinical & translational aspects. Cancer Genetics Inc. and Applied BioMath have confirmed their participation as sponsors at the congress and will be showcasing their latest products and solutions. Cancer Genetics Inc. - Platinum Sponsor at the congress will give a presentation on day one, whereas John Burke, Co-Founder, President and CEO at Applied BioMath will present on day two.

The congress will be an excellent opportunity for the attendees to learn about the latest industry developments, meet experts from pharma and bio-pharma companies and share their research experience. The delegates will also get a chance to present their work in the form of posters at the congress.

http://www.mnmconferences.com/

About MarketsandMarkets Conferences: 

MarketsandMarkets Conferences (MnM Conferences) produces global summits, congresses and conferences bringing together key industry experts from academia and industry sharing and exchanging ideas and latest research through cutting edge conference programs and interactive panel and round table discussions.

Media Contact: 
Ajay Nimbalkar
Tel: +91-20-6708 0270
Email: ajay.nimbalkar@marketsandmarkets.com
Twitter: https://twitter.com/mnmconferences
LinkedIn: https://www.linkedin.com/company/mnm-conferences


SOURCE MarketsandMarkets Conferences